ZFIN ID: ZDB-FIG-151016-11
Wang et al., 2015 - First quantitative high-throughput screen in zebrafish identifies novel pathways for increasing pancreatic β-cell mass. eLIFE   4 Full text @ Elife
Anatomical Term:
Stage: Day 5
Observed In:
Stage: Day 5

Fig. 3

Validation of endocrine differentiation induction: precocious 2° islet assay.

(A, B) Representative confocal images - brightfield and fluorescence images merged - of dissected pancreata (dashed lines) from neurod:EGFP transgenic larvae treated from 3 to 5 dpf with 0.1% DMSO (A) or a Hit I drug (B, example shown is parthenolide). Early endocrine cells are labeled with GFP (green) allowing precocious formation of 2° islets (white arrows) to be visualized following drug exposures. (C) The number of precocious 2° islets was quantified following treatment with the indicated Hit I compounds from 3 to 5 dpf. Results obtained with the optimal concentration were plotted relative to negative (0.1% DMSO) and positive controls (RO2949097, 5 µM). Of 20 Hit I compounds tested, 11 were confirmed as Lead I drugs for inducing endocrine differentiation (optimal concentrations for validated leads are shown in parentheses). Arrows indicate drugs that inhibit NF-κB signaling. Scale bar, 25 µm. Error bars, standard error. All p-values were calculated using Dunnett′s test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n = 5–10 larvae per condition, experiment was repeated 3 times per compound.

Gene Expression Details
Gene Antibody Fish Conditions Stage Anatomy Assay
EGFP nl1Tg control Day 5 pancreas endocrine cell IFL
nl1Tg chemical treatment: parthenolide Day 5 pancreas endocrine cell IFL
Antibody Labeling Details No data available
Phenotype Details
Fish Conditions Stage Phenotype
nl1Tg chemical treatment: parthenolide Day 5 secondary islet endocrine pancreas development premature, abnormal
ZFIN wishes to thank the journal eLIFE for permission to reproduce figures from this article. Please note that this material may be protected by copyright. Full text @ Elife